Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Depreciation & Amortization (CF) (2016 - 2024)

Spero Therapeutics' Depreciation & Amortization (CF) history spans 9 years, with the latest figure at $2000.0 for Q2 2024.

  • For Q2 2024, Depreciation & Amortization (CF) fell 98.15% year-over-year to $2000.0; the TTM value through Mar 2025 reached $2000.0, down 99.21%, while the annual FY2024 figure was $2000.0, 99.46% down from the prior year.
  • Depreciation & Amortization (CF) reached $2000.0 in Q2 2024 per SPRO's latest filing, down from $38000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $294000.0 in Q2 2022 to a low of $2000.0 in Q2 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $157882.4, with a median of $159000.0 recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 307.21% in 2020, then tumbled 98.15% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $230000.0 in 2020, then fell by 16.96% to $191000.0 in 2021, then plummeted by 32.46% to $129000.0 in 2022, then tumbled by 70.54% to $38000.0 in 2023, then plummeted by 94.74% to $2000.0 in 2024.
  • Per Business Quant, the three most recent readings for SPRO's Depreciation & Amortization (CF) are $2000.0 (Q2 2024), $38000.0 (Q4 2023), and $108000.0 (Q3 2023).